Regorafenib is intended to treat patients with metastatic colorectal cancer whose disease has progressed after standard therapy.
FDA grants priority review to medicines that provide a treatment where little or no adequate therapy exists. FDA completes a priority review within six months of receiving the new drug application rather than the standard 10-month review cycle.
The application for regorafenib was filed at the end of April.
Related Articles on Colon Cancer:
Study: CT Colonography Effective Screening Tool for Colon Cancer
Univ. of FL Researchers Receive $1.5M to Study Colon Cancer
‘Pill Colonoscopy’ Under Development in Boston
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
